Author:
White Ian N.H.,Carthew Philip,Davies Reginald,Styles Jerry,Brown Karen,Brown John E.,Smith Lewis L.,Martin Elizabeth A.
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,General Medicine
Reference34 articles.
1. Baum,M. (1998) Tamoxifen—The treatment of choice. Why look for alternatives? Br. J. Cancer, 78, 1–4.
2. Fisher,B., Costantino,J.P., Wickerham,D.L. et al. (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst., 90, 1371–1388.
3. Fisher,B., Dignam,J., Bryant,J. et al. (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl Cancer Inst., 88, 1529–1542.
4. Carthew,P., Rich,K.J., Martin,E.A., De Matteis,F., Lim,C.K., Manson,M.M., Festing,M.F., White,I.N. and Smith,L.L. (1995) DNA damage as assessed by 32P-post-labelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. Carcinogenesis, 16, 1299–1304.
5. Hard,G.C., Iatropoulos,M.J., Jordan,K., Radi,L., Kaltenberg,O.P., Imondi,A.R. and Williams,G.M. (1993) Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Cr1: CD(BR) rats. Cancer Res., 53, 4534–4541.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Transgenic rat models for mutagenesis and carcinogenesis;Genes and Environment;2017-02-01
2. Toxicology and Adverse Drug Reactions;Stephens' Detection and Evaluation of Adverse Drug Reactions;2012-01-30
3. Detailed review of transgenic rodent mutation assays;Mutation Research/Reviews in Mutation Research;2005-09
4. ��-Hydroxytamoxifen 97170-41-7;Sax's Dangerous Properties of Industrial Materials;2004-10-15
5. Tamoxifen cytotoxicity in hepatoblastoma cells stably transfected with human CYP3A4;Biochemical Pharmacology;2004-03